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Abstract Granulocyte-colony-stimulating factor (G-
CSF)-induced hematopoietic stem and progenitor cell
(HSPC) mobilization is associated with the release of
neutrophil-derived proteases. Previously, we have shown
that alpha-1-antitrypsin (AAT) inhibits these proteases in
mice, resulting in inhibition of HSPC mobilization. Here,
we studied the relationship between AAT and HSPC in
steady state and cytokine-induced mobilization in humans.
Patients with alpha-1-antitrypsin deficiency (AATD) have
an 85–90 % decrease of AAT in the peripheral blood (PB).
We hypothesized that this leads to increased proteolytic
activity in the bone marrow and increased steady-state PB
HSPC numbers. Using flow cytometry and semi-solid cell
culture, we found no significant difference in PB HSPC in
AATD patients (n = 18) as compared to controls (n = 22).
Healthy stem cell donors (n = 43) were mobilized with
G-CSF for 5 days and the number of CD45?/CD34? HSPC
were determined in PB. We found that, during mobiliza-
tion, PB AAT levels increased significantly, positively
correlating with PB CD45?/CD34? cells (r = 0.31,
p = 0.005). In conclusion, although serum AAT levels and
HSPC mobilization in healthy stem cell donors are posi-
tively correlated, AAT is not an indispensable protease-
inhibitor in the constitutive circulation of HSPC. These
findings suggest a model in which both protease-dependent
and -independent pathways contribute to HSPC
mobilization.
Keywords Stem cells  Alpha-1-antitrypsin deficiency 
Hematopoietic stem cell mobilization  Granulocyte-
colony-stimulating factor
Introduction
Granulocyte-colony-stimulating factor (G-CSF) mobilized
stem and progenitor cells (HSPC) are routinely used as a
source for clinical stem cell transplantation. In recent years,
research has started to unravel the mechanisms underlying
cytokine-induced HSPC mobilization. G-CSF administra-
tion induces expansion and activation of hematopoietic
progenitor cells in the bone marrow, which leads to
increased numbers of neutrophils [1, 2]. Upon activation,
neutrophils release proteases, including neutrophil elastase
(NE), cathepsin G (CG) and matrix metalloproteinase-9
(MMP-9) [3–6]. These proteases degrade adhesive inter-
actions between HSPC and their microenvironment,
including CXCR4/CXCL12, VLA-4/VCAM-1 and c-KIT/
SCF [5, 7, 8]. Levels of CXCL12, a chemokine that attracts
HSPC, are down regulated in the BM, which induces a
gradient, allowing HSPC to mobilize towards the periph-
eral blood [8]. Furthermore, administration of G-CSF
induces apoptosis of trophic endosteal macrophages (os-
teomacs) that support osteoblast function [9]. These oste-
oblasts are an important constituent of the stem cell niche
and play a critical role in HSPC maintenance, via soluble
and membrane-bound factors such as CXCL12 and SCF
[10]. During G-CSF-induced HSPC mobilization, expres-
sion of alpha-1-antitrypsin (AAT) is strongly reduced in
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osteoblasts, both at the protein and mRNA levels [11, 12].
Alpha-1-antitrypsin is a potent inhibitor of serine proteases,
including NE and CG. Decreased levels of AAT are
associated with an accumulation of active proteases in the
bone marrow compartment, resulting in HSPC mobiliza-
tion from the bone marrow towards the peripheral blood
[12]. Increased levels of AAT, either by induction via low-
dose irradiation or via intraperitoneal administration of
exogenous AAT, result in a near-complete inhibition of
HSPC mobilization in mice [13]. In the peripheral blood of
G-CSF-mobilized healthy individuals, proteases such as
MMP-9 and NE, are significantly increased as compared to
non-mobilized donors [14–16]. Thus far, peripheral blood
levels of AAT during G-CSF-induced HSPC mobilization
in humans have not been studied.
The importance of the balance between proteases and
protease-inhibitors in retention and mobilization of HSPC
suggests that modulation of AAT levels could be a novel
strategy to induce HSPC mobilization. To test this hypoth-
esis, we studied the presence of HSPC in the peripheral
blood of patients with alpha-1-antitrypsin deficiency
(AATD). AATD patients have a mutation in the gene
responsible for the expression of AAT, SERPINA1, result-
ing in severely decreased serum levels of AAT as only
10–15 % of AAT is released into the circulation. As a result,
the lungs of these patients are exposed to enzymatic damage
by proteases such as NE, leading to early-onset emphysema
and bronchiectasis [17–19]. Such a constitutively decreased
AAT level, as observed in AATD patients, could lead to a
protease/protease-inhibitor imbalance with elevated protease
activity in the bone marrow. Increased proteolytic activity
may degrade adhesive interactions between HSPC and their
environment and as a result steady-state peripheral blood
HSPC frequencies could be affected in these patients.
Therefore, we determined the number of CD45?/CD34?
cells, as well as the frequency of colony-forming cells in the
peripheral blood in a cohort of AATD patients.
In addition, to determine the relationship between serum
AAT levels and mobilizing capacity, we investigated
HSPC frequencies in the peripheral blood of G-CSF-




During routine follow-up visits to the pulmonology out-
patient clinic, blood samples were taken from patients with
AATD. All samples were taken between 8 a.m. and 10 a.m.
to minimize the possible effect of the circadian rhythm on
HSPC mobilization [20]. All patients had a ZZ-phenotype
(PI*ZZ) as confirmed by isoelectric focusing. Healthy
volunteers and patients with chronic obstructive pulmonary
disease (COPD) levels were used as controls. Individuals
with a C-reactive protein (CRP) level C5 lg/ml or non-
MM phenotype were excluded from the analysis. Blood
samples were analyzed for AAT level, AAT phenotype and
HSPC frequency. The levels of two other physiologically
important protease-inhibitors, alpha-2-macroglobulin
(A2M) and secretory leukocyte proteinase inhibitor (SLPI),
were also determined [21].
Human donors undergoing G-CSF-induced stem cell
mobilization
Healthy allogeneic peripheral blood stem cell donors were
mobilized by injection of recombinant-human-G-CSF
(Filgrastim; Amgen, Thousand Oaks, CA), which was
given subcutaneously at a dose of 10 lg/kg on days 1–3.
On day 4, two doses of 10 lg/kg were given, one in the
morning and one in the evening approximately 12 h before
the onset of apheresis on day 5. On days 3, 4, and 5, blood
samples were taken prior to G-CSF administration to
determine white blood cell counts, neutrophil counts and
the frequency of CD34? cells, as described previously [16].
Plasma samples were collected to determine AAT levels.
All donors gave informed consent and the local ethical
committee approved this protocol.
Determination of peripheral blood HSPC
Peripheral blood HSPC were determined by flow cytometry
and by HSPC culture. For flow cytometric analysis,
peripheral blood mononuclear cells (PBMC) were co-
stained with conjugated monoclonal antibodies against
CD45 (PE, clone HI30) and CD34 (FITC, clone 8G12)
after red blood cell lysis with NH4Cl (LUMC Pharmacy,
Leiden). Antibodies were obtained from BD PharMingen,
San Diego, CA. HSPC were defined as the FSClo/SSClo/
CD45?/CD34? fraction.
To determine the frequency of HSPC by semi-solid cell
culture, 2.0 9 105 PBMC, obtained after Ficoll separation
of heparinized whole blood, were plated in 3.5-cm dishes
according to the manufacturer’s recommendations
(Methocult H4434 Classic, Stemcell Technologies, Gre-
noble, France). After 12–14 days of culture in a fully
humidified atmosphere of 37 C containing 5 % CO2, the
number of colonies was scored using an inverted light
microscope. Colonies were scored according to the type of
progenitors they contained: granulocytes (CFU-G), mono-
cytes (CFU-M), granulocytes and monocytes (CFU-GM),
granulocytes, monocytes and erythroid progenitors (CFU-
GEMM) or erythroid progenitors only [CFU-E and burst-
forming colony (BFU)-E].
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Determination of plasma levels of protease-inhibitors
and AAT phenotype
Serum levels of AAT were measured quantitatively by
radial immunodiffusion using commercially available
plates (NOR Partigen, Siemens, Germany). A2M and SLPI
levels were measured using an enzyme-linked immuno-
sorbent assay using a polyclonal rabbit anti-human A2M
antibody (DAKO, Glostrup, Denmark) and human anti-
SLPI antibody (clone 31, Hycult Biotech, Uden, The
Netherlands), respectively.
AAT phenotype was determined by isoelectric focusing;
subjects were divided in having a MM-phenotype (normal),
ZZ-phenotype (AATD patients) or other phenotype (e.g.,
MZ or SS).
Statistical analysis
Statistical differences were determined using GraphPadP-
RISM (GraphPad Software, San Diego, CA). Data are pre-
sented as mean values ± standard error of the mean (SEM);
p Values of \0.05 were considered statistically significant.
Spearman’s correlation coefficient (r) was used to describe
the strength of association between two ranked variables.
Results
Hematopoietic stem cell frequencies in the peripheral
blood of AATD patients and healthy controls are
similar
To investigate the relationship between serum levels of
peripheral blood AAT and steady-state peripheral blood
HSPC frequencies, patients with AATD were compared
with healthy volunteers. To exclude the possibility that the
results would be biased by the presence of chronic lung
disease alone, a second control group consisting of patients
with COPD was included. In total, 20 healthy controls, 21
patients with AATD and 12 patients with COPD were
studied. In the healthy control group, 6 subjects were
excluded from the analysis (n = 3 due to a non-MM
phenotype; n = 3 due to a CRP level C5 lg/ml). In the
AATD patient group and in the COPD patient group, 3 and
4 subjects, respectively, were excluded because of a CRP
level C5 lg/ml. Therefore, 18 patients in the AATD group,
14 healthy controls and 8 COPD patients were available for
further analysis. Patient characteristics were comparable,
with the exception of age, which was higher in the COPD
patient group (Table 1). As expected, serum AAT levels in
AATD patients were significantly decreased compared to
both control groups (0.21 ± 0.04 vs. 1.80 ± 0.32 mg/ml,
respectively, p \ 0.0001). No significant differences were
observed in A2M or SLPI levels between healthy controls
and AATD patients (Fig. 1a, b).
Subsequently, the absolute number of CD45?/CD34?
cells was determined by flow cytometry. No significant
difference was observed for the AATD patients as com-
pared to both control groups (AATD patients 3.2 9
10-3 ± 2.0 9 10-3/ml, healthy controls 2.2 9 10-3 ±
0.9 9 10-3/ml, COPD patients 2.2 9 10-3 ± 2.7 9 10-3/
ml, p = 0.12 for comparison between AATD patients and
healthy controls, p = 0.35 for comparison between AATD
patients and COPD patients; Fig. 1c).
Next, CFU-C frequencies were determined by colony
assays in semi-solid cultures. No significant difference was
observed between the three groups with respect to the
peripheral blood frequency of CFU-G/M/GM/GEMM
(AATD patients 281.0 ± 178.0 colonies/106 PBMC,
healthy controls 259.5 ± 75.8 colonies/106 PBMC and
COPD patients 223.4 ± 96.5 colonies/106 PBMC;
p = 0.67 for comparison between AATD patients and
healthy controls, p = 0.40 for comparison between AATD
patients and COPD patients; Fig. 1d). However, the
peripheral blood frequency of BFU-E was significantly
increased in the AATD patients group as compared to
healthy controls (AATD patients 357.2 ± 167.8 colonies/
106 PBMC, healthy controls 159.3 ± 67.1 colonies/106
PBMC), but was lower than BFU-E frequencies in COPD
patients (612.5 ± 464.0 colonies/106 PBMC, p \ 0.05 for
comparison between all groups; Fig. 1e). No significant
correlation was found between the serum AAT level, the
absolute number of CD45?/CD34? cells (r = -0.18,
p = 0.53) and the total number of CFU-G/M/GM/GEMM
(r = -0.19, p = 0.50; data not shown).
In conclusion, very low serum levels of AAT are not
associated with changes in steady-state HSPC frequencies
in the peripheral blood of patients with AATD.
AAT serum levels are increased during G-CSF-induced
HSPC mobilization in healthy human donors
To investigate the effect of G-CSF administration on AAT
levels in peripheral blood, 43 healthy human HSPC donors
(mean age 40.9 years, range 16–65 years; 26 males, 17
females) were treated with G-CSF for 4 consecutive days.
On days 3, 4 and 5 serum AAT levels and CD45?/CD34?







AATD patients 18 52.3 ± 12.2 22–69 ZZ
Healthy controls 14 39.3 ± 11.6 22–61 MM
COPD patients 8 63.9 ± 6.0 55–71 MM
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numbers in peripheral blood were determined. In peripheral
blood, CD45?/CD34? numbers increased significantly
from 14.2 9 103/ml ± 10.5 9 103/ml on day 3 to
99.9 9 103/ml ± 56.0 9 103/ml on day 5 (p \ 0.0001 for
day 3 vs. day 5; Fig. 2a). Similarly, AAT levels increased
significantly from day 3 to day 5 of G-CSF administration
(AAT 1.40 mg/ml ± 0.20 mg/ml, 1.47 mg/ml ± 0.22 mg/
ml and 1.54 mg/ml ± 0.25 mg/ml on day 3, 4 and 5,
respectively; p \ 0.0001 for day 3 vs. day 5; Fig. 2b). To
examine whether CD45?/CD34? numbers and AAT levels
were correlated, a Spearman correlation test was applied. A
higher number of peripheral blood CD45?/CD34? cells
was associated with a higher level of serum AAT
(r = 0.31, p = 0.005; Fig. 2c).
Neutrophil numbers and neutrophil elastase levels in the
peripheral blood are positively correlated with the extent of
HSPC mobilization [16]. Therefore, we investigated the
relationship between neutrophil numbers, neutrophil elas-
tase and AAT levels. An increase in neutrophil numbers is
positively associated with a concurrent increase in AAT
levels (r = 0.49, p \ 0.0001; Fig. 2d). Furthermore, a
concomitant increase was observed for white blood cell
counts and AAT. No correlation was found for MMP-9
levels and AAT.
In conclusion, G-CSF-induced HSPC mobilization in
human donors is associated with a concomitant increase in
peripheral blood AAT levels between days 3 and 5 of
mobilization.
Fig. 1 Hematopoietic stem cell
frequencies in the peripheral
blood of AATD patients are not
significantly different as
compared to healthy volunteers
and patients with COPD. No
significant differences were
observed in a A2M or b SLPI
levels in peripheral blood serum
obtained from healthy controls
and AATD patients. c The
absolute number of CD45?/
CD34? cells/ml peripheral
blood was determined by FACS
analysis. AATD patients are
compared with healthy controls
and COPD patients (p C 0.10).
The frequency of HSPC in the
peripheral blood was obtained
by semi-solid cell culture of
2.0 9 105 PBMC. Colonies
were manually scored according
to the type of progenitors they
contained: d myeloid (CFU-G/
M/GM/GEMM) or e erythroid
progenitors (BFU-E)
(*p = 0.048, **p = 0.016 and
***p = 0.0003)
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Discussion
Steady-state HSPC content of peripheral blood in healthy
persons is relatively low compared to the HSPC content of
bone marrow [22]. Peripheral blood HSPC numbers may
increase upon internal signals (inflammation, tissue injury)
or external signals (cytokines, drugs). We have previously
found that HSPC frequencies in the peripheral blood are
significantly reduced in germ-free mice and that these
numbers increase upon addition of endotoxin to the
drinking water [23]. These results indicate that the ‘‘con-
stitutive’’ presence of HSPC in the peripheral blood is
actually, at least in part, an induced event, most likely in
response to bacterial products. In addition, the level of
mobilization is determined by a balance between proteases
and their inhibitors, such as AAT [13]. We therefore
hypothesized that HSPC frequencies in patients with a
deficiency of AAT are increased. However, our study
shows that in these patients the frequency of peripheral
blood steady-state HSPC is not significantly different from
controls. The higher number of BFU-E in patients with
AATD or COPD most likely reflects a physiological
response to a chronic hypoxic condition. The lack of dif-
ferences in peripheral blood steady-state numbers of HSPC
could not be explained by a compensatory increase in other
protease-inhibitors, as A2M or SLPI levels did not signif-
icantly differ between healthy controls and AATD patients.
During G-CSF-induced HSPC mobilization in humans,
increased levels of proteases are present in the peripheral
blood [16]. In the current report, we show that serum AAT
levels increase on days 3–5 of G-CSF-induced HSPC
mobilization in healthy donors. Furthermore, serum AAT
levels are positively correlated with HSPC mobilization.
The increase in serum AAT levels most likely is a response
to the high serum levels of proteases that is observed
during G-CSF-induced mobilization in healthy human
donors [16]. In this previous study, NE levels increased
about 40-fold on day 3 of G-CSF-induced HSPC mobili-
zation as compared to levels at the onset of G-CSF
administration. Since AAT binds irreversibly to NE as soon
as it is released into the peripheral circulation, an increase
in serum NE during HSPC mobilization will likely induce a
concomitant increase in serum AAT. In mice, we have
observed a similar phenomenon, as serum levels of AAT
Fig. 2 G-CSF-induced peripheral blood HSPC mobilization in
human donors in relation to serum alpha-1-antitrypsin levels.
a Peripheral blood CD45?/CD34? numbers were determined by flow
cytometry in the peripheral blood of human peripheral stem cell
donors on days 3, 4 and 5 of G-CSF administration. b Levels of AAT
are measured quantitatively through radial immunodiffusion in the
serum of human peripheral stem cell donors on days 3, 4 and 5 of
G-CSF administration (**p \ 0.0001). c CD45?/CD34? numbers are
shown in correlation with serum AAT levels in G-CSF mobilized
peripheral stem cell donors (r = 0.31, p = 0.005). d Serum AAT
levels and neutrophil numbers/ml of peripheral blood are positively
correlated at day 5 of G-CSF-induced HSPC mobilization (r = 0.49,
p \ 0.0001)
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increase during G-CSF-induced HSPC mobilization (M.P.,
unpublished data). The increase of AAT levels in the
peripheral blood is in contrast with the decrease of AAT
levels that is shown in murine bone marrow during G-CSF-
induced HSPC mobilization [12]. Similar to what is
observed in mice, it can be postulated that in humans AAT
levels in the bone marrow are decreased. However, since
bone marrow AAT levels were not measured in our study,
we were not able to confirm this hypothesis.
During recent years, it became clear that besides the
secretion of proteases, other mechanisms also play a role in
HSPC mobilization. Mice that are conditionally deficient
for one or more proteases including MMP-9, NE and CG
mobilize in response to G-CSF [24]. Furthermore, a role
has been observed for osteal macrophages and osteoblasts
[9, 25, 26].
In conclusion, we show that AAT is unlikely to be an
indispensable protease-inhibitor in the constitutive circu-
lation of HSPC, suggesting a complex model in which both
protease-dependent and -independent pathways may con-
tribute to HSPC mobilization.
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